ERBB2 and breast carcinoma: This study was designed for a direct intrapatient comparison of the distribution and targeting properties of [99mTc]Tc-ADAPT6 and [99mTc]Tc-(HE)3-G3 in HER2-positive breast cancer patients before systemic treatment with trastuzumab in combination with chemotherapy.